非白喉棒状杆菌抗菌药物敏感性回顾分析(2012-2023)
该研究回顾分析了2012年1月至2023年3月Mayo Clinic微生物实验室1,925株非白喉棒状杆菌的抗菌药物敏感性。主要菌种为纹带棒状杆菌(35.6%)和无枝菌酸棒状杆菌(24.4%)。青霉素敏感性从2012年的47.5%降至2023年的20.6%,红霉素从22.4%降至13.2%。利奈唑胺和万古霉素对所有菌株体外均有效。
要点
- 青霉素和红霉素敏感性逐年下降,经验性用药需谨慎。
- 利奈唑胺和万古霉素对所有非白喉棒状杆菌体外均有效。
- 纹带棒状杆菌多重耐药常见,慢性抑制治疗患者挑战大。
核心结论
- 非白喉棒状杆菌对青霉素和红霉素敏感性下降,利奈唑胺和万古霉素普遍有效,菌种间敏感性差异显著,应进行药敏试验指导治疗。
研究设计与样本
- 回顾性分析2012年1月至2023年3月Mayo Clinic微生物实验室1,925株非白喉棒状杆菌的抗菌药物敏感性试验结果,排除可能携带白喉毒素的菌种。
主要发现
- 纹带棒状杆菌占35.6%,无枝菌酸棒状杆菌占24.4%。
- 青霉素敏感性从2012年的47.5%(58/122)降至2023年的20.6%(14/68)。
- 红霉素敏感性从2012年的22.4%(26/116)降至2023年的13.2%(9/68)。
- 复方磺胺甲噁唑敏感性在整个期间平均约50%。
- 利奈唑胺和万古霉素对所有菌种体外均有效。
关键数值与推荐
- 青霉素敏感性2012年47.5%(58/122),2023年20.6%(14/68)。
- 红霉素敏感性2012年22.4%(26/116),2023年13.2%(9/68)。
- 复方磺胺甲噁唑敏感性平均约50%。
- 达托霉素MIC>256 µg/mL见于1株无枝菌酸棒状杆菌、1株结核硬脂酸棒状杆菌和7株纹带棒状杆菌,均来自既往达托霉素暴露患者。
- 达托霉素MIC 2 µg/mL(非敏感)见于1株来自无达托霉素暴露患者的纹带棒状杆菌和6株杰氏棒状杆菌(来自暴露和非暴露患者)。
临床怎么用
- 非白喉棒状杆菌感染应进行抗菌药物敏感性试验以指导治疗。
- 利奈唑胺和万古霉素可作为经验性覆盖非白喉棒状杆菌的可靠选择。
- 纹带棒状杆菌多重耐药者需警惕,尤其需长期抑制治疗的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A total of 1,925 Corynebacterium isolates were tested for antimicrobial susceptibility at the Mayo Clinic Microbiology laboratory (Rochester, Minnesota) from January 2012 to March 2023, with C. striatum (35.6%) and C. amycolatum (24.4%) identified as the predominant species. Species known to potentially carry diphtheria toxin were excluded. Common sources of isolation included skin and soft tissue (56.8%), bone and/or native joint synovial fluid (14.2%), urine (13.1%), sputum (6.1%), and blood (5.9%). For penicillin, susceptibility decreased from 47.5% (58 of 122) in 2012 to 20.6% (14 of 68) in 2023. Isolates also showed a decrease in susceptibility to erythromycin from 22.4% (26 of 116) in 2012 to 13.2% (9 of 68) in 2023. Susceptibility to trimethoprim-sulfamethoxazole averaged around 50% throughout the period. Notably, linezolid and vancomycin were universally effective in vitro against all species. The highest susceptibility rates among tested oral agents were to linezolid and doxycycline for non-C. striatum species. Daptomycin minimal inhibitory concentrations (MICs) of >256 µg/mL were observed for one C. amycolatum isolate, one C. tuberculostearicum isolate, and for seven C. striatum isolates, all from patients with prior daptomycin exposure. Daptomycin MICs of 2 µg/mL (nonsusceptible) were observed in one C. striatum isolate recovered from a daptomycin-naïve patient and in six C. jeikeium isolates, from both daptomycin-exposed and non-exposed patients. Significant variation in susceptibility profiles across different Corynebacterium species underscores the importance of performing antimicrobial susceptibility testing to guide effective treatment. Moreover, multidrug resistance observed in C. striatum poses substantial therapeutic challenges especially in patients requiring prolonged or chronic antibiotic suppression.
引用
- Khodadadi RB, El Zein S, Rivera O'Connor CG, et al. Retrospective analysis of antimicrobial susceptibility profiles of non-diphtheriae Corynebacterium species from a tertiary hospital and reference laboratory, 2012-2023. J Clin Microbiol. 2024. PMID: 39555924. doi:10.1128/jcm.01199-24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。